Table 1.
Baseline characteristics in analysis A
| Characteristics | N | Total (N = 788) | IgAN (n = 499) | MN (n = 67) | FSGS (n = 53) | Crescentic GN (n = 61) | Classic DN (n = 46) | Nephrosclerosis (n = 52) |
|---|---|---|---|---|---|---|---|---|
| Age (years), mean (SD) | 778 | 56 (12) | 54 (12) | 66 (7) | 55 (12) | 63 (10) | 60 (12) | 56 (11) |
| Male, n (%) | 778 | 426 (54.8) | 246 (49.3) | 48 (71.6) | 34 (64.2) | 32 (52.5) | 27 (58.7) | 39 (75.0) |
| History of DM, n (%) | 778 | 175 (22.5) | 64 (12.8) | 17 (25.4) | 15 (28.3) | 23 (37.7) | 46 (100.0) | 10 (19.2) |
| eGFR, (mL/min/1.73 m2), mean (SD) | 778 | 32 (12) | 32 (13) | 32 (10) | 31 (11) | 28 (12) | 27 (12) | 32 (13) |
| CKD stage, n (%) | 778 | |||||||
| 3a | 115 (14.8) | 85 (17.0) | 9 (13.4) | 4 (7.5) | 5 (8.2) | 5 (10.9) | 7 (13.5) | |
| 3b | 307 (39.5) | 198 (39.7) | 31 (46.3) | 23 (43.4) | 19 (31.1) | 13 (28.3) | 23 (44.2) | |
| 4 | 274 (35.2) | 161 (32.3) | 23 (34.3) | 22 (41.5) | 28 (45.9) | 22 (47.8) | 18 (34.6) | |
| 5 | 82 (10.5) | 55 (11.0) | 4 (6.0) | 4 (7.5) | 9 (14.8) | 6 (13.0) | 4 (7.7) | |
| UACR, n (%) | 723 | 514 (167–1219) | 423 (164–1001) | 778 (137–3159) | 945 (551–1775) | 185 (46–349) | 1931 (727–3481) | 569 (165–986) |
| <30 | 49 (6.8) | 29 (6.3) | 7 (10.9) | 1 (2.0) | 10 (17.9) | 1 (2.3) | 1 (2.1) | |
| 30–300 | 222 (30.7) | 154 (33.5) | 12 (18.8) | 7 (13.7) | 27 (48.2) | 4 (9.1) | 18 (37.5) | |
| ≥300 | 452 (62.5) | 277 (60.2) | 45 (70.3) | 43 (84.3) | 19 (33.9) | 39 (88.6) | 29 (60.4) | |
| History of any CVD, n (%) | 778 | 110 (14.1) | 52 (10.4) | 11 (16.4) | 12 (22.6) | 14 (23.0) | 15 (32.6) | 6 (11.5) |
| History of CAD, n (%) | 778 | 60 (7.7) | 28 (5.6) | 8 (11.9) | 8 (15.1) | 6 (9.8) | 6 (13.0) | 4 (7.7) |
| History of CHF, n (%) | 778 | 13 (1.7) | 6 (1.2) | 1 (1.5) | 0 (0.0) | 1 (1.6) | 4 (8.7) | 1 (1.9) |
| History of stroke, n (%) | 778 | 36 (4.6) | 15 (3.0) | 4 (6.0) | 3 (5.7) | 8 (13.1) | 6 (13.0) | 0 (0.0) |
| History of PAD, n (%) | 778 | 16 (2.1) | 8 (1.6) | 0 (0.0) | 1 (1.9) | 1 (1.6) | 5 (10.9) | 1 (1.9) |
| History of respiratory diseases, n (%) | 778 | 85 (10.9) | 36 (7.2) | 10 (14.9) | 8 (15.1) | 16 (26.2) | 5 (10.9) | 10 (19.2) |
| Medication, n (%) | ||||||||
| Any antihypertensive agents | 778 | 727 (93.4) | 462 (92.6) | 63 (94.0) | 52 (98.1) | 54 (88.5) | 46 (100.0) | 50 (96.2) |
| ACEi/ARB | 778 | 684 (87.9) | 441 (88.4) | 61 (91.0) | 46 (86.8) | 47 (77.0) | 43 (93.5) | 46 (88.5) |
| Diuretics | 778 | 172 (22.1) | 75 (15.0) | 32 (47.8) | 9 (17.0) | 16 (26.2) | 31 (67.4) | 9 (17.3) |
| ESA | 778 | 77 (9.9) | 35 (7.0) | 10 (14.9) | 3 (5.7) | 10 (16.4) | 13 (28.3) | 6 (11.5) |
| Active vitamin D | 778 | 68 (8.7) | 39 (7.8) | 8 (11.9) | 7 (13.2) | 8 (13.1) | 5 (10.9) | 1 (1.9) |
| Antiplatelet | 778 | 100 (12.9) | 46 (9.2) | 11 (16.4) | 8 (15.1) | 13 (21.3) | 14 (30.4) | 8 (15.4) |
| Laboratory data | ||||||||
| Albumin (g/dL) | 758 | 4.0 (0.4) | 4.0 (0.4) | 3.6 (0.6) | 3.9 (0.4) | 3.9 (0.3) | 3.7 (0.5) | 4.1 (0.4) |
| Hemoglobin (g/dL), mean (SD) | 763 | 12.3 (1.9) | 12.3 (1.7) | 12.0 (1.8) | 12.8 (2.0) | 11.9 (1.7) | 10.9 (1.9) | 13.3 (2.4) |
| Phosphate (mg/dL), mean (SD) | 682 | 3.5 (0.6) | 3.5 (0.6) | 3.5 (0.6) | 3.3 (0.5) | 3.4 (0.7) | 4.0 (0.6) | 3.3 (0.6) |
| Intact PTH (pg/mL), median (IQR) | 725 | 70 (50–106) | 70 (49–102) | 63 (40–87) | 80 (57–127) | 72 (59–104) | 89 (64–171) | 68 (47–99) |
| 25-hydroxy vitamin D (ng/ml), median (IQR) | 715 | 15.4 (9.6–23.0) | 16.6 (9.9–25.0) | 12.4 (7.3–17.7) | 13.9 (8.4–21.0) | 19.2 (11.6–24.9) | 10.3 | |
| (6.1–15.4) | 15.1 | |||||||
| (12.0–21.7) |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.